SonR®  Sensor

The SonR® CRT system, composed of the SonR^® CRT-D + SonR^® Tip Atrial Lead, is the first and only solution to use a cardiac contractility sensor embedded in an atrial lead to automate CRT optimization. 

Paired with an advanced proprietary optimization algorithm, it enables personalized AV and VV interval adjustments based on real-time hemodynamic feedback, supporting improved response and long-term therapy performance.

• Continuous measurement of the heart's contractility allowing for automatic optimization of AV and VV intervals.
• Weekly optimization at rest and during exercise.
• 35% risk reduction in Heart Failure (HF) hospitalization.¹

Addressing variability in CRT response with automated, personalized therapy.

Despite advances in CRT, up to 30% of patients may not respond as expected.² SonR® addresses this variability by:

• Continuously measuring cardiac contractility: Providing a direct, objective assessment of the heart's pumping performance.³
• Adapting AV and VV intervals weekly, at rest, and during activity: Ensuring therapy is consistently optimized, not just at implant, but dynamically at rest and during physical activity.
• Supporting effective CRT therapy in complex patient subgroups: Offering a tailored approach for those historically known for lower CRT response rates.^1,4

The power of SonR® lies in its unique two-part system, designed to provide continuous, adaptive therapy:

     1. SonR® Tip Atrial Lead 

At the core of the system, the SonR® sensor is embedded in the tip of the atrial lead. It detects vibrations from myocardial contractions, which correlate with LV dP/dt max, providing a reliable indicator for cardiac contractility.

• Over 99% implant success rate
• Proven handling and torque stability for effortless positioning
• Predictable and stable electrical performance over time

     2. SonR® Optimization Algorithm

The SonR® CRT-D device uses the SonR® sensor input to automatically optimize AV and VV intervals weekly, at rest and during activity, without requiring echocardiographic input or in-clinic reprogramming.

This allows cardiac resynchronization therapy to be continuously adapted to each patient's individual needs, ensuring optimal filling time while preserving contraction effectiveness over time.⁷

The effectiveness and safety of SonR®-guided CRT optimization have been rigorously validated in the RESPOND-CRT™ Trial¹, a large, randomized, double-blind, multicenter, landmark study. 

The trial successfully met its primary endpoint, demonstrating that automatic AV & VV optimization with SonR® technology is as safe and effective as AV and VV optimization using echocardiography.

• High Clinical Response: 75% clinical responder rate in the SonR® arm vs. 70% in control (p<0.001) at 12 months.¹
• Non-Inferiority: Confirmed non-inferiority to echo-guided optimization for the primary endpoint.¹
• Reduced Hospitalization Risk: 35% risk reduction in heart failure hospitalization compared to echo-optimized therapy¹
• Proven successful implantation rate: 99.8% SonR® Tip implant success rate with freedom from complications: >98.5%¹

Subgroup analysis from the RESPOND-CRT trial showed higher clinical response and reduced HF hospitalization risk in patients with high risk of non-response, including:

• Patients with atrial fibrillation history: -45% reduction in all-cause mortality or HF hospitalization^1,4,5
• Patients with renal dysfunction: -52% reduction^1,4,5
• Patients with LBBB and QRS <150ms: -38% reduction^1,4,5

SonR® Optimization is available when connecting the SonR® Tip lead with:

• Platinium™ 4LV SonR® CRT-D
• Gali™ 4LV SonR® CRT-D
• Talentia™ 4LV SonR® CRT-D

Gain insights from leading clinicians on the impact of SonR® technology.